Patents by Inventor Christopher T. Harbison

Christopher T. Harbison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING TUMOR
    Publication number: 20220195046
    Abstract: The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score and a tumor that has a high tumor mutation burden (TMB) status. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ming LEI, Nathan O. SIEMERS, Dimple PANDYA, Han CHANG, Teresa K. SANCHEZ, Christopher T. HARBISON, Peter M. SZABO, Zachary S. BOYD, Xiaozhong QIAN, Samy Abdel SACI, Tina C. YOUNG, Sujaya SRINIVASAN, Megan M. WIND-ROTOLO, Jasmine RIZZO, Donald G. JACKSON, Alice M. WALSH
  • METHODS OF TREATING TUMOR
    Publication number: 20220041733
    Abstract: The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.
    Type: Application
    Filed: March 27, 2020
    Publication date: February 10, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ming LEI, Nathan O. SIEMERS, Dimple PANDYA, Han CHANG, Teresa K. SANCHEZ, Christopher T. HARBISON, Peter M. SZABO, Zachary S. BOYD, Alice M. WALSH
  • Biologically-active DNA-binding sites and related methods
    Patent number: 7611838
    Abstract: The invention relates to the identification of biologically-active DNA-binding sites to which a protein of interest binds in a cell. The invention also relates to the identification of agents and conditions which alter the biologically-active DNA-binding sites to which a protein binds. One aspect of the invention also provides methods for identifying pathways that are regulated by transcriptional regulators and for modulating the activity of the pathways.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: November 3, 2009
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Christopher T. Harbison, Richard A. Young, David B. Gordon, Ernest Fraenkel
  • Novel Methods for Genome-Wide Location Analysis
    Publication number: 20090143240
    Abstract: The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that use tiled arrays. The invention also provides methods of identifying the transcriptional rate of the gene in a cell. The invention also relates to methods of performing genome-wide location analysis, and ChIP-CHIP analysis, using histones and modified histones.
    Type: Application
    Filed: August 25, 2006
    Publication date: June 4, 2009
    Inventors: Christopher T. Harbison, Richard A. Young, Dmitry K. Pokholok